Two chemokines, RANTES/CCL5 and ENA-78/CXCL5 showed similar, albeit milder dynamics to PDGF proteins in prostate cancer patients before treatment (3653 pg mean with 1068–6239 pg 95% CI and 325 pg mean with 211–439 pg 95% CI in patients before treatment versus 1339 pg mean with 1090–1589 pg 95% CI and 163 pg mean with 114–211 pg 95% CI in healthy controls for RANTES and ENA-78, respectively), and returned to control values by month 6 (Figure 8C,D). Here, CCL5 is linked to prostate carcinoma.